Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta Sells 8,283 Shares

Liquidia Co. (NASDAQ:LQDA - Get Free Report) CFO Michael Kaseta sold 8,283 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $112,400.31. Following the completion of the sale, the chief financial officer now directly owns 396,315 shares of the company's stock, valued at $5,377,994.55. This trade represents a 2.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Liquidia Stock Down 3.1 %

LQDA traded down $0.43 during trading on Monday, hitting $13.29. The company's stock had a trading volume of 678,752 shares, compared to its average volume of 968,593. The firm's 50 day moving average price is $14.65 and its two-hundred day moving average price is $12.82. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -8.15 and a beta of 0.23. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.81.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, sell-side analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Corebridge Financial Inc. lifted its position in Liquidia by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company's stock valued at $371,000 after acquiring an additional 694 shares in the last quarter. Catalina Capital Group LLC boosted its stake in shares of Liquidia by 6.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock worth $215,000 after acquiring an additional 1,125 shares during the period. GAMMA Investing LLC increased its holdings in shares of Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock valued at $44,000 after purchasing an additional 1,173 shares during the last quarter. Cetera Investment Advisers raised its holdings in Liquidia by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock valued at $367,000 after acquiring an additional 1,277 shares during the period. Finally, Summit Investment Advisors Inc. increased its stake in shares of Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the period. Institutional investors own 64.54% of the company's stock.

Analyst Upgrades and Downgrades

LQDA has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC reissued a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a research report on Thursday, April 10th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).